ClinicalTrials.gg
CompletedNCT02075593Updated Oct 6, 2022Results posted

ING200336, Pharmacokinetic and Safety Study in Pregnant Women With Human Immuno Virus Infection

A Phase 3 interventional study of DTG 50 mg /ABC 600 mg /3TC 300 mg FDC tablets in Infection, Human Immunodeficiency Virus, HIV Infections and Arthralgia, sponsored by ViiV Healthcare. Completed at 3 sites in 2 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-10-06.

Primary conditionHIV InfectionsRegistry: InfectionsReclassifiedWhy we changed it
Registry
Infections — the first condition term the registry derived for this study.
ClinicalTrials.gg
HIV Infections
Why
  1. The study's listed conditions name HIV Infections, a narrower term within Infections.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by ViiV Healthcare (part of GlaxoSmithKline) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
4
Allocation
Not applicable
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 55 studies testing dolutegravir in HIV Infections — 7 open to participants now, 9 under way, 4 of them phase 3. Dolutegravir · HIV Infections.

Enrollment
55th of 55
4 · median 126
Started
2014
with 3 others
Phase 3
21 of 55
2 open now
Registered
13th of 55
by date
Lead sponsor
26 of 55
ViiV Healthcare

Among the 55 studies testing dolutegravir in HIV Infections, this one is the 55th largest by enrollment, is one of 4 that started in 2014, is one of 21 in phase 3, and was the 13th registered.

HIV Infections

4,737 studies on the registry are indexed under HIV Infections; 246 are open to participants now.

Browse HIV Infections studies →

Open to participants now

7 of the 55 studies testing dolutegravir in HIV Infections are open now, in 12 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

About dolutegravir

Dolutegravir: first FDA approval 2013 (TIVICAY), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 159 HIV Infections studies recruiting now, 104 (65%) set no upper age limit and 42 (26%) stop at 75 or younger; 31 take children under 18; 60 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 55 studies testing dolutegravir in HIV Infections, or all of them as a file.
02

Study summary

In this study, the dolutegravir/abacavir/lamivudine (DTG/ABC/3TC) fixed dose combination (FDC) tablet is being made available to women who become pregnant while participating in study ING117172. Continuation of antiretroviral therapy (ART) is key to both mother and the unborn fetus in order to maintain virologic suppression in the mother (thereby decreasing the risk for maternal disease progression), but also to reduce the risk of maternal-fetal transmission of human immunodeficiency virus type 1 (HIV-1) to her unborn child. This study also offers the first opportunity to investigate the impact of pregnancy on DTG pharmacokinetics (PK). This is an open-label, single arm interventional study. The number of women that will be enrolled into this study cannot be established a priori, as unintended pregnancies cannot be determined in advance. The maximum number of women would include all of those women randomized to DTG/ABC/3TC FDC (approximately 237), though unintended pregnancies in all of these women would not be anticipated.

03

Conditions studied

  • Infection, Human Immunodeficiency Virus
  • HIV Infections
  • Arthralgia

Browse trials for

Keywords

  • dolutegravir/abacavir/lamivudine fixed dose combination
  • pregnant women
  • once daily
  • antiretroviral therapy-naive
  • HIV-1 Infection
  • integrase inhibitor
04

In context

HIV Infections Reclassified

4,737 studies on the registry are indexed under HIV Infections; 246 are open to participants now.

This study's enrollment of 4 is below the median of 80 across 3,491 interventional studies indexed under HIV Infections.

Browse HIV Infections studies →

Lead sponsor

ViiV Healthcare is the lead sponsor of 267 studies on the registry; 18 are open to participants now.

Of its 71 completed or terminated interventional studies of FDA-regulated products, 53 (75%) have results posted.

Compared within HIV Infections, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Infections. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • infected females participating in ING117172 on the DTG/ABC/3TC treatment arm who became pregnant with a singleton and have not met any safety or confirmed virologic withdrawal criteria.
  • Signed and dated written is obtained from the subject or the subject's legal representative prior to screening.
  • Willingness and intent to continue pregnancy
  • Willingness to continue to receive DTG/ABC/3TC FDC.
  • Willingness to enter the Antiretroviral Pregnancy Registry.
  • Willingness to share medical information about herself and her infant for collection of delivery and infant outcomes as it relates to this study.
  • Subjects enrolled in France: a subject will be eligible for inclusion in this study only if either affiliated to or a beneficiary of a social security category.

Exclusion criteria

Exclusion Criteria:

  • History of allergy/sensitivity to DTG, ABC and/or 3TC.
  • History of severe pre-clampsia, eclampsia, or hemolysis, elevated liver enzymes and low count (HELLP)
  • Any evidence of an active Center for Disease Control and Prevention (CDC) Category C disease, except cutaneous Kaposi's sarcoma not requiring systemic therapy or historic or current CD4+ cell levels \<200 cells/millimeter\^3.
  • Subjects with any degree of hepatic impairment.
  • Ongoing other than cutaneous Kaposi's sarcoma, basal cell carcinoma, or resected, non-invasive cutaneous squamous cell carcinoma, or cervical intraepithelial neoplasia; other localized malignancies require agreement between the investigator and the Study medical monitor for inclusion of the subject.
  • Subjects who in the investigator's judgment, poses a significant suicidality risk. Recent history of suicidal behavior and/or suicidal ideation may be considered as evidence of serious suicide risk.
  • Subjects with evidence of ongoing infection at screening, or anticipated need for Virus therapy during the study.
  • Treatment with any of the following agents within 28 days of Baseline: radiation therapy; cytotoxic chemotherapeutic agents; any immunomodulators that alter immune responses.
  • Subjects enrolled in France: the subject has participated in any study using an drug during the previous 60 days or 5 half-lives, or twice the duration of the biological effect of the experimental drug or vaccine, whichever is longer, prior to screening for the study or the subject will participate simultaneously in another clinical study.
  • Any verified Grade 4 laboratory abnormality with the exception of Grade 4 lipid abnormalities (total cholesterol, triglycerides, high density lipoprotein [HDL] cholesterol, low density lipoprotein [LDL] cholesterol). A single repeat test is allowed during the Screening period to verify a result.
  • Any acute laboratory abnormality observed in ING117172 or in any Screening laboratory assessments for ING200336, which, in the opinion of the Investigator, would preclude the subject's participation in the study.
  • Hyperbilirubinemia of unknown etiology.
  • Confirmed (with no more than 1 repeat evaluation) Grade >= 2 urine protein (dipstick), serum creatinine, total , or aspartate aminotransferase at the time of the screening lab.
  • Subject has of \<50 mL/minute via Cockroft-Gault method at the time of the screening visit
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

06

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
4 participants (actual)

Study arms

  • Experimental
    DTG/ABC/3TC

    All subjects will be administered DTG 50 milligrams (mg)/ABC 600 mg/3TC 300 mg FDC tablet once daily, with or without food.

    Drug: DTG 50 mg /ABC 600 mg /3TC 300 mg FDC tablets

Interventions

  • DrugDTG 50 mg /ABC 600 mg /3TC 300 mg FDC tablets

    Drug page: Dolutegravir

    The DTG 50 mg /ABC 600 mg /3TC 300 mg FDC tablet is a purple, oval, biconvex tablets. The tablet contains 52.6 mg DTG sodium which is equivalent to 50 mg DTG free acid, 702 mg ABC sulphate which is equivalent to 600 mg ABC and 300 mg 3TC.

07

What researchers measure

Primary outcomes

  1. Area Under the Plasma Concentration Time Curve at Steady State During a Dosing Interval (AUC [0-tau]) for Dolutegravir

    Blood samples were collected at indicated timepoints for Pharmacokinetic (PK) analysis of dolutegravir at Trimester 2 (Weeks 18-26 of pregnancy), Trimester 3 (Weeks 30-36 of pregnancy) and at 8-12 Weeks postpartum.

    Time frame: Pre-dose and at 1, 2, 3, 4, 6, 8, 12, 24 hours post-dose at Trimester 2 (Weeks 18-26 of pregnancy), Trimester 3 (Weeks 30-36 of pregnancy) and at 8-12 Weeks postpartum

  2. Maximum Observed Plasma Concentration (Cmax) for Dolutegravir

    Blood samples were collected at indicated timepoints for PK analysis of dolutegravir at Trimester 2 (Weeks 18-26 of pregnancy), Trimester 3 (Weeks 30-36 of pregnancy) and at 8-12 Weeks postpartum.

    Time frame: Pre-dose and at 1, 2, 3, 4, 6, 8, 12, 24 hours post-dose at Trimester 2 (Weeks 18-26 of pregnancy), Trimester 3 (Weeks 30-36 of pregnancy) and at 8-12 Weeks postpartum

  3. Drug Concentration at the End of Dosing Interval (Ctau) for Dolutegravir

    Blood samples were collected at indicated timepoints for PK analysis of dolutegravir at Trimester 2 (Weeks 18-26 of pregnancy), Trimester 3 (Weeks 30-36 of pregnancy) and at 8-12 Weeks postpartum.

    Time frame: 24 hours post dose at Trimester 2 (Weeks 18-26 of pregnancy), Trimester 3 (Weeks 30-36 of pregnancy) and at 8-12 Weeks postpartum

  4. Apparent Oral Clearance (CL/F) for Dolutegravir

    Blood samples were collected at indicated timepoints for PK analysis of dolutegravir at Trimester 2 (Weeks 18-26 of pregnancy), Trimester 3 (Weeks 30-36 of pregnancy) and at 8-12 Weeks postpartum.

    Time frame: Pre-dose and at 1, 2, 3, 4, 6, 8, 12, 24 hours post-dose at Trimester 2 (Weeks 18-26 of pregnancy), Trimester 3 (Weeks 30-36 of pregnancy) and at 8-12 Weeks postpartum

  5. Steady State Volume of Distribution (Vss/F) After Extravascular Administration for Dolutegravir

    Blood samples were collected at indicated timepoints for PK analysis of dolutegravir at Trimester 2 (Weeks 18-26 of pregnancy), Trimester 3 (Weeks 30-36 of pregnancy) and at 8-12 Weeks postpartum.

    Time frame: Pre-dose and at 1, 2, 3, 4, 6, 8, 12, 24 hours post-dose at Trimester 2 (Weeks 18-26 of pregnancy), Trimester 3 (Weeks 30-36 of pregnancy) and at 8-12 Weeks postpartum

  6. Half-life (T1/2) for Dolutegravir

    Blood samples were collected at indicated timepoints for PK analysis of dolutegravir at Trimester 2 (Weeks 18-26 of pregnancy), Trimester 3 (Weeks 30-36 of pregnancy) and at 8-12 Weeks postpartum.

    Time frame: Pre-dose and at 1, 2, 3, 4, 6, 8, 12, 24 hours post-dose at Trimester 2 (Weeks 18-26 of pregnancy), Trimester 3 (Weeks 30-36 of pregnancy) and at 8-12 Weeks postpartum

  7. Number of Participants (Pregnant Women) With Maximum Severity of Post-Baseline Emergent Hematology Toxicities: Hemoglobin

    Blood samples were collected for analysis of hemoglobin. Any abnormality was graded according to Division of Acquired Immunodeficiency Syndrome (DAIDS) toxicity scales from Grade 1 to 4 (1=Mild, 2=Moderate, 3=Severe, 4=Potentially life threatening). Number of participants (Pregnant Women) with maximum severity of post-Baseline emergent toxicities with respect to hemoglobin has been presented.

    Time frame: Up to Week 32 of study

  8. Absolute Values of the Chemistry Parameters: Alanine Aminotransferase (ALT) and Aspartate Aminotransferase (AST)

    Blood samples were collected for the analysis of chemistry parameters including ALT and AST.

    Time frame: At Baseline (Day 1), Week 4, Week 8, Week 12, Week 16, Week 20, Week 24 and Week 32 of study

  9. Change From Baseline in Chemistry Parameters: ALT and AST

    Blood samples were collected for the analysis of chemistry parameters including ALT and AST. Baseline value (Day 1) is the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline is defined as post-dose visit value minus Baseline value.

    Time frame: Baseline and at Week 4, Week 8, Week 12, Week 16, Week 20, Week 24 and Week 32 of study

  10. Absolute Values of the Chemistry Parameters: Bilirubin and Creatinine

    Blood samples were collected for the analysis of chemistry parameters including Bilirubin and Creatinine.

    Time frame: At Baseline (Day 1), Week 4, Week 8, Week 12, Week 16, Week 20, Week 24 and Week 32 of study

  11. Change From Baseline in Chemistry Parameters: Bilirubin and Creatinine

    Blood samples were collected for the analysis of chemistry parameters including Bilirubin and Creatinine. Baseline value (Day 1) is the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline is defined as post-dose visit value minus Baseline value.

    Time frame: Baseline and at Week 4, Week 8, Week 12, Week 16, Week 20, Week 24 and Week 32 of study

  12. Absolute Values of the Hematology Parameters: Hemoglobin

    Blood samples were collected for the analysis of hematology parameters including hemoglobin.

    Time frame: At Baseline (Day 1), Week 4, Week 8, Week 12, Week 16, Week 20, Week 24 and Week 32 of study

  13. Change From Baseline in Hematology Parameters: Hemoglobin

    Blood samples were collected for the analysis of hematology parameters including hemoglobin. Baseline value (Day 1) is the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline is defined as post-dose visit value minus Baseline value.

    Time frame: Baseline and at Week 4, Week 8, Week 12, Week 16, Week 20, Week 24 and Week 32 of study

  14. Absolute Values of the Hematology Parameters: Leukocytes and Platelets

    Blood samples were collected for the analysis of hematology parameters including leukocytes and platelets.

    Time frame: At Baseline (Day 1), Week 4, Week 8, Week 12, Week 16, Week 20, Week 24 and Week 32 of study

  15. Change From Baseline in Hematology Parameters: Leukocytes and Platelets

    Blood samples were collected for the analysis of hematology parameters including leukocytes and platelets. Baseline value (Day 1) is the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline is defined as post-dose visit value minus Baseline value.

    Time frame: Baseline and at Week 4, Week 8, Week 12, Week 16, Week 20, Week 24 and Week 32 of study

  16. Number of Participants (Pregnant Women) Who Discontinued the Treatment Due to Adverse Events (AE)

    An AE is any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a study treatment. Number of participants (pregnant women) who discontinued the treatment due to adverse events have been presented.

    Time frame: Up to Week 292

  17. Number of Participants (Pregnant Women) Demonstrated Congenital Malformations

    Data for participants (pregnant women) demonstrated congenital malformations was reported.

    Time frame: At delivery (up to Week 40 of pregnancy)

  18. Number of Participants (Pregnant Women) With Adverse Events (AE) as Per Severity Grades

    Number of participants (pregnant women) with adverse events (AE) as per severity grades were presented. Grade 1 is mild, grade 2 is moderate, grade 3 is severe or medically significant but not immediately life-threatening and grade 4 is life-threatening consequences; urgent intervention required.

    Time frame: Up to 292 Weeks

Secondary outcomes

  1. Time to Cmax (Tmax) for Dolutegravir

    Blood samples were collected at indicated timepoints for PK analysis of dolutegravir at Trimester 2 (Weeks 18-26 of pregnancy), Trimester 3 (Weeks 30-36 of pregnancy) and at 8-12 Weeks postpartum.

    Time frame: Pre-dose and at 1, 2, 3, 4, 6, 8, 12, 24 hours post-dose at Trimester 2 (Weeks 18-26 of pregnancy), Trimester 3 (Weeks 30-36 of pregnancy) and at 8-12 Weeks postpartum

  2. Pre-dose Plasma Concentration (C0) for Dolutegravir

    Blood samples were collected at indicated timepoints for PK analysis of dolutegravir at Trimester 2 (Weeks 18-26 of pregnancy), Trimester 3 (Weeks 30-36 of pregnancy) and at 8-12 Weeks postpartum.

    Time frame: Pre-dose at Trimester 2 (Weeks 18-26 of pregnancy), Trimester 3 (Weeks 30-36 of pregnancy) and at 8-12 Weeks postpartum

  3. Unbound DTG Concentrations in Plasma at 3 and 24 Hours Post Dose of Dolutegravir

    Blood samples were collected at indicated timepoints for PK analysis of dolutegravir at Trimester 2 (Weeks 18-26 of pregnancy), Trimester 3 (Weeks 30-36 of pregnancy) and at 8-12 Weeks postpartum.

    Time frame: At 3 hours and 24 hours post dose in Trimester 2 (Weeks 18-26 of pregnancy), Trimester 3 (Weeks 30-36 of pregnancy) and at 8-12 Weeks postpartum

  4. Total DTG Concentrations in Plasma From Cord Blood and Maternal Blood at the Time of Delivery

    Blood samples were collected at the time of delivery for PK analysis of dolutegravir.

    Time frame: At delivery (up to Week 40 of pregnancy)

  5. Number of Participants (Pregnant Women) With Treatment-emergent Genotypic and/or Phenotypic Resistance Who Met Confirmed Virologic Withdrawal Criteria

    Number of participants (pregnant women) with treatment-emergent genotypic and/or phenotypic resistance who met confirmed virologic withdrawal criteria are presented. Genotypic and phenotypic analyses were carried out by Monogram Biosciences using, but not limited to, their Standard Phenosense and GenoSure testing methods for protease (PRO) and reverse transcriptase (RT), or with their GeneSeq Integrase and PhenoSense Integrase assays.

    Time frame: Up to Week 32 of study

  6. Number of Participants (Pregnant Women) With Live Birth Outcome Categories

    Participants (pregnant women) with following live birth outcome categories are reported- Vaginal Birth, Planned Caesarean Section, Unscheduled Caesarean Section and Preterm Delivery.

    Time frame: At delivery (up to Week 40 of pregnancy)

  7. Gestational Age of Infants

    Gestational age is defined as the number of weeks between the first day of the mother's last normal menstrual period and the day of birth. Data for gestational age of infants has been presented.

    Time frame: At birth

  8. Neonatal Length and Head Circumference at Birth

    Data for neonatal length and head circumference at birth are reported.

    Time frame: At birth

  9. Neonatal Weight at Birth

    Data for neonatal weight at birth has been reported.

    Time frame: At birth

  10. Number of Infants by Their Weight Categories at Birth

    Weight of infants at birth were categorized as: Small for Gestational Age (SGA) defined neonates under the 10th percentile in weight, Appropriate for Gestational Age (AGA) characterized neonates between the 10th and 90th percentiles in weight and Large for Gestational Age (LGA) referred to neonates over the 90th percentile in weight.

    Time frame: At birth

  11. Number of Infants by Appearance, Pulse, Grimace, Activity, and Respiration (APGAR) Score at 1 and 5 Minutes After Birth

    APGAR is a quick test to assess the health of new born. The test is performed at 1 and 5 minutes after birth. APGAR scale is determined by evaluating the new born on five categories (appearance, pulse, grimace, activity and respiration) on a scale from zero to two with 2 being the best score, then summing up the values obtained from all five categories. APGAR score ranges from 0 to 10 (Higher score indicates better health) where a score of 7 and above is normal. Number of infants by APGAR score at 1 and 5 minutes after birth are presented.

    Time frame: 1 and 5 minutes after birth

  12. Percentage of Participants (Pregnant Women) With Plasma Human Immunodeficiency Virus Type 1 (HIV-1) Ribonucleic Acid (RNA) <50 Copies/Milliliter (c/mL) by Visit

    Percentage of participants (pregnant women) with plasma HIV-1 RNA \<50 c/mL are presented. Plasma samples were collected for quantitative analysis of HIV-1 RNA.

    Time frame: At Week 4, Week 8, Week 12, Week 16, Week 20, Week 24, Week 28 and Week 32 of study

  13. Percentage of Participants (Pregnant Women) With Plasma HIV-1 RNA <400 c/mL by Visit

    Percentage of participants (pregnant women) with plasma HIV-1 RNA \<400 c/mL are presented. Plasma samples were collected for quantitative analysis of HIV-1 RNA.

    Time frame: At Week 4, Week 8, Week 12, Week 16, Week 20, Week 24, Week 28 and Week 32 of study

  14. Absolute Values of Cluster of Differentiation 4 (CD4+) T Cell Counts by Visit

    Blood samples were collected for the analysis of CD4+ T cell counts using cytometry.

    Time frame: At Baseline (Day 1), Week 4, Week 8, Week 12, Week 16, Week 20, Week 24, Week 28 and Week 32 of study

  15. Change From Baseline in CD4+ T Cell Counts by Visit

    Blood samples were collected for the analysis of CD4+ T cell counts using cytometry. Baseline value (Day 1) is the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline is defined as post-dose visit value minus Baseline value.

    Time frame: Baseline and at Week 4, Week 8, Week 12, Week 16, Week 20, Week 24, Week 28 and Week 32 of study

  16. Number of Participants (Pregnant Women) With Disease Progression

    Disease progression included HIV-associated conditions, acquired immunodeficiency syndrome (AIDS) and death. Number of participants (pregnant women) with disease progression to Centers for Disease Control and Prevention (CDC) class C or death have been presented.

    Time frame: Up to Week 32 of study

08

Results

Posted Feb 18, 2022

Participant flow

This is a single arm open-label study in women who became pregnant while participating in study ING117172 (NCT01910402).

Participant flow — Overall Study
MilestoneDTG/ABC/3TC - Mother
Started4
Infants born to pregnant women who received at least one dose of study treatment4
Completed3
Not completed1
Withdrew: Withdrawal by subject1

Outcome measures

PrimaryArea Under the Plasma Concentration Time Curve at Steady State During a Dosing Interval (AUC [0-tau]) for Dolutegravir

Blood samples were collected at indicated timepoints for Pharmacokinetic (PK) analysis of dolutegravir at Trimester 2 (Weeks 18-26 of pregnancy), Trimester 3 (Weeks 30-36 of pregnancy) and at 8-12 Weeks postpartum.

Time frame:
Pre-dose and at 1, 2, 3, 4, 6, 8, 12, 24 hours post-dose at Trimester 2 (Weeks 18-26 of pregnancy), Trimester 3 (Weeks 30-36 of pregnancy) and at 8-12 Weeks postpartum
Reported as:
Geometric mean · Micrograms*hours per milliliter
Area Under the Plasma Concentration Time Curve at Steady State During a Dosing Interval (AUC [0-tau]) for Dolutegravir
Micrograms*hours per milliliterDTG/ABC/3TC - Mother
Trimester 2 (Weeks 18-26 of pregnancy)55.045 (37.918 to 79.907)
Trimester 3 (Weeks 30-36 of pregnancy)42.473 (27.613 to 65.330)
8-12 Weeks postpartum78.917 (53.195 to 117.075)
PrimaryMaximum Observed Plasma Concentration (Cmax) for Dolutegravir

Blood samples were collected at indicated timepoints for PK analysis of dolutegravir at Trimester 2 (Weeks 18-26 of pregnancy), Trimester 3 (Weeks 30-36 of pregnancy) and at 8-12 Weeks postpartum.

Time frame:
Pre-dose and at 1, 2, 3, 4, 6, 8, 12, 24 hours post-dose at Trimester 2 (Weeks 18-26 of pregnancy), Trimester 3 (Weeks 30-36 of pregnancy) and at 8-12 Weeks postpartum
Reported as:
Geometric mean · Micrograms per milliliter
Maximum Observed Plasma Concentration (Cmax) for Dolutegravir
Micrograms per milliliterDTG/ABC/3TC - Mother
Trimester 2 (Weeks 18-26 of pregnancy)4.420 (2.906 to 6.724)
Trimester 3 (Weeks 30-36 of pregnancy)3.424 (2.038 to 5.753)
8-12 Weeks Postpartum5.578 (3.866 to 8.049)
PrimaryDrug Concentration at the End of Dosing Interval (Ctau) for Dolutegravir

Blood samples were collected at indicated timepoints for PK analysis of dolutegravir at Trimester 2 (Weeks 18-26 of pregnancy), Trimester 3 (Weeks 30-36 of pregnancy) and at 8-12 Weeks postpartum.

Time frame:
24 hours post dose at Trimester 2 (Weeks 18-26 of pregnancy), Trimester 3 (Weeks 30-36 of pregnancy) and at 8-12 Weeks postpartum
Reported as:
Geometric mean · Nanograms per milliliter
Drug Concentration at the End of Dosing Interval (Ctau) for Dolutegravir
Nanograms per milliliterDTG/ABC/3TC - Mother
Trimester 2 (Weeks 18-26 of pregnancy)930.1 (562.0 to 1539.3)
Trimester 3 (Weeks 30-36 of pregnancy)657.5 (266.1 to 1624.4)
8-12 Weeks Postpartum2154.7 (901.4 to 5150.5)
PrimaryApparent Oral Clearance (CL/F) for Dolutegravir

Blood samples were collected at indicated timepoints for PK analysis of dolutegravir at Trimester 2 (Weeks 18-26 of pregnancy), Trimester 3 (Weeks 30-36 of pregnancy) and at 8-12 Weeks postpartum.

Time frame:
Pre-dose and at 1, 2, 3, 4, 6, 8, 12, 24 hours post-dose at Trimester 2 (Weeks 18-26 of pregnancy), Trimester 3 (Weeks 30-36 of pregnancy) and at 8-12 Weeks postpartum
Reported as:
Geometric mean · Liters per hour
Apparent Oral Clearance (CL/F) for Dolutegravir
Liters per hourDTG/ABC/3TC - Mother
Trimester 2 (Weeks 18-26 of pregnancy)0.739 (0.484 to 1.130)
Trimester 3 (Weeks 30-36 of pregnancy)0.952 (0.559 to 1.620)
8-12 Weeks Postpartum0.464 (0.062 to 3.476)
PrimarySteady State Volume of Distribution (Vss/F) After Extravascular Administration for Dolutegravir

Blood samples were collected at indicated timepoints for PK analysis of dolutegravir at Trimester 2 (Weeks 18-26 of pregnancy), Trimester 3 (Weeks 30-36 of pregnancy) and at 8-12 Weeks postpartum.

Time frame:
Pre-dose and at 1, 2, 3, 4, 6, 8, 12, 24 hours post-dose at Trimester 2 (Weeks 18-26 of pregnancy), Trimester 3 (Weeks 30-36 of pregnancy) and at 8-12 Weeks postpartum
Reported as:
Geometric mean · Liters
Steady State Volume of Distribution (Vss/F) After Extravascular Administration for Dolutegravir
LitersDTG/ABC/3TC - Mother
Trimester 2 (Weeks 18-26 of pregnancy)9.665 (6.651 to 14.044)
Trimester 3 (Weeks 30-36 of pregnancy)12.326 (7.878 to 19.285)
8-12 Weeks Postpartum6.326 (0.048 to 833.336)
PrimaryHalf-life (T1/2) for Dolutegravir

Blood samples were collected at indicated timepoints for PK analysis of dolutegravir at Trimester 2 (Weeks 18-26 of pregnancy), Trimester 3 (Weeks 30-36 of pregnancy) and at 8-12 Weeks postpartum.

Time frame:
Pre-dose and at 1, 2, 3, 4, 6, 8, 12, 24 hours post-dose at Trimester 2 (Weeks 18-26 of pregnancy), Trimester 3 (Weeks 30-36 of pregnancy) and at 8-12 Weeks postpartum
Reported as:
Mean · Hours
Half-life (T1/2) for Dolutegravir
HoursDTG/ABC/3TC - Mother
Trimester 2 (Weeks 18-26 of pregnancy)9.215 ± 1.8968
Trimester 3 (Weeks 30-36 of pregnancy)9.401 ± 3.0322
8-12 Weeks Postpartum9.699 ± 3.0427
PrimaryNumber of Participants (Pregnant Women) With Maximum Severity of Post-Baseline Emergent Hematology Toxicities: Hemoglobin

Blood samples were collected for analysis of hemoglobin. Any abnormality was graded according to Division of Acquired Immunodeficiency Syndrome (DAIDS) toxicity scales from Grade 1 to 4 (1=Mild, 2=Moderate, 3=Severe, 4=Potentially life threatening). Number of participants (Pregnant Women) with maximum severity of post-Baseline emergent toxicities with respect to hemoglobin has been presented.

Time frame:
Up to Week 32 of study
Reported as:
Count of participants · Participants
Number of Participants (Pregnant Women) With Maximum Severity of Post-Baseline Emergent Hematology Toxicities: Hemoglobin
ParticipantsDTG/ABC/3TC - Mother
Grade 11
Grade 20
Grade 30
Grade 40
PrimaryAbsolute Values of the Chemistry Parameters: Alanine Aminotransferase (ALT) and Aspartate Aminotransferase (AST)

Blood samples were collected for the analysis of chemistry parameters including ALT and AST.

Time frame:
At Baseline (Day 1), Week 4, Week 8, Week 12, Week 16, Week 20, Week 24 and Week 32 of study
Reported as:
Mean · International units per Liter
Absolute Values of the Chemistry Parameters: Alanine Aminotransferase (ALT) and Aspartate Aminotransferase (AST)
International units per LiterDTG/ABC/3TC - Mother
ALT, Baseline (Day 1), n=410.8 ± 5.56
ALT, Week 4, n=415.3 ± 4.43
ALT, Week 8, n=419.3 ± 17.21
ALT, Week 12, n=411.0 ± 3.16
ALT, Week 16, n=410.8 ± 2.36
ALT, Week 20, n=410.3 ± 7.27
ALT, Week 24, n=119.0 ± NA
ALT, Week 32, n=228.0 ± 15.56
AST, Baseline (Day 1), n=414.8 ± 4.19
AST, Week 4, n=417.3 ± 2.22
AST, Week 8, n=417.3 ± 6.18
AST, Week 12, n=415.0 ± 1.83
AST, Week 16, n=414.8 ± 2.63
AST, Week 20, n=416.3 ± 3.30
AST, Week 24, n=120.0 ± NA
AST, Week 32, n=224.0 ± 8.49
PrimaryChange From Baseline in Chemistry Parameters: ALT and AST

Blood samples were collected for the analysis of chemistry parameters including ALT and AST. Baseline value (Day 1) is the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline is defined as post-dose visit value minus Baseline value.

Time frame:
Baseline and at Week 4, Week 8, Week 12, Week 16, Week 20, Week 24 and Week 32 of study
Reported as:
Mean · International units per Liter
Change From Baseline in Chemistry Parameters: ALT and AST
International units per LiterDTG/ABC/3TC - Mother
ALT, Week 4, n=44.5 ± 6.03
ALT, Week 8, n=48.5 ± 11.79
ALT, Week 12, n=40.3 ± 3.30
ALT, Week 16, n=40.0 ± 3.56
ALT, Week 20, n=4-0.5 ± 1.73
ALT, Week 24, n=10.0 ± NA
ALT, Week 32, n=219.5 ± 14.85
AST, Week 4, n=42.5 ± 4.43
AST, Week 8, n=42.5 ± 2.38
AST, Week 12, n=40.3 ± 3.10
AST, Week 16, n=40.0 ± 3.37
AST, Week 20, n=41.5 ± 1.29
AST, Week 24, n=1-1.0 ± NA
AST, Week 32, n=211.0 ± 8.49
PrimaryAbsolute Values of the Chemistry Parameters: Bilirubin and Creatinine

Blood samples were collected for the analysis of chemistry parameters including Bilirubin and Creatinine.

Time frame:
At Baseline (Day 1), Week 4, Week 8, Week 12, Week 16, Week 20, Week 24 and Week 32 of study
Reported as:
Mean · Micromoles per Liter
Absolute Values of the Chemistry Parameters: Bilirubin and Creatinine
Micromoles per LiterDTG/ABC/3TC - Mother
Bilirubin, Baseline (Day 1), n=47.3 ± 3.77
Bilirubin, Week 4, n=45.0 ± 1.83
Bilirubin, Week 8, n=45.5 ± 2.65
Bilirubin, Week 12, n=44.5 ± 1.29
Bilirubin, Week 16, n=44.5 ± 1.29
Bilirubin, Week 20, n=44.5 ± 1.29
Bilirubin, Week 24, n=17.0 ± NA
Bilirubin, Week 32, n=26.5 ± 0.71
Creatinine, Baseline (Day 1), n=457.73 ± 16.661
Creatinine, Week 4, n=450.50 ± 2.990
Creatinine, Week 8, n=451.58 ± 3.067
Creatinine, Week 12, n=450.68 ± 3.293
Creatinine, Week 16, n=447.45 ± 2.001
Creatinine, Week 20, n=450.60 ± 6.424
Creatinine, Week 24, n=163.60 ± NA
Creatinine, Week 32, n=268.90 ± 3.677
PrimaryChange From Baseline in Chemistry Parameters: Bilirubin and Creatinine

Blood samples were collected for the analysis of chemistry parameters including Bilirubin and Creatinine. Baseline value (Day 1) is the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline is defined as post-dose visit value minus Baseline value.

Time frame:
Baseline and at Week 4, Week 8, Week 12, Week 16, Week 20, Week 24 and Week 32 of study
Reported as:
Mean · Micromoles per Liter
Change From Baseline in Chemistry Parameters: Bilirubin and Creatinine
Micromoles per LiterDTG/ABC/3TC - Mother
Bilirubin, Week 4, n=4-2.3 ± 2.06
Bilirubin, Week 8, n=4-1.8 ± 1.26
Bilirubin, Week 12, n=4-2.8 ± 2.99
Bilirubin, Week 16, n=4-2.8 ± 2.99
Bilirubin, Week 20, n=4-2.8 ± 2.99
Bilirubin, Week 24, n=1-5.0 ± NA
Bilirubin, Week 32, n=22.0 ± 2.83
Creatinine, Week 4, n=4-7.23 ± 14.014
Creatinine, Week 8, n=4-6.15 ± 16.700
Creatinine, Week 12, n=4-7.05 ± 14.328
Creatinine, Week 16, n=4-10.28 ± 17.453
Creatinine, Week 20, n=4-7.13 ± 11.154
Creatinine, Week 24, n=1-19.10 ± NA
Creatinine, Week 32, n=219.10 ± 3.253
PrimaryAbsolute Values of the Hematology Parameters: Hemoglobin

Blood samples were collected for the analysis of hematology parameters including hemoglobin.

Time frame:
At Baseline (Day 1), Week 4, Week 8, Week 12, Week 16, Week 20, Week 24 and Week 32 of study
Reported as:
Mean · Grams per Liter
Absolute Values of the Hematology Parameters: Hemoglobin
Grams per LiterDTG/ABC/3TC - Mother
Baseline (Day 1), n=4127.8 ± 11.24
Week 4, n=4120.8 ± 7.23
Week 8, n=4113.5 ± 7.05
Week 12, n=4116.5 ± 7.14
Week 16, n=4115.0 ± 4.69
Week 20, n=4115.8 ± 8.30
Week 24, n=1127.0 ± NA
Week 32, n=2140.5 ± 0.71
PrimaryChange From Baseline in Hematology Parameters: Hemoglobin

Blood samples were collected for the analysis of hematology parameters including hemoglobin. Baseline value (Day 1) is the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline is defined as post-dose visit value minus Baseline value.

Time frame:
Baseline and at Week 4, Week 8, Week 12, Week 16, Week 20, Week 24 and Week 32 of study
Reported as:
Mean · Grams per Liter
Change From Baseline in Hematology Parameters: Hemoglobin
Grams per LiterDTG/ABC/3TC - Mother
Week 4, n=4-7.0 ± 10.17
Week 8, n=4-14.3 ± 7.37
Week 12, n=4-11.3 ± 4.92
Week 16, n=4-12.8 ± 6.65
Week 20, n=4-12.0 ± 4.97
Week 24, n=1-14.0 ± NA
Week 32, n=214.0 ± 8.49
PrimaryAbsolute Values of the Hematology Parameters: Leukocytes and Platelets

Blood samples were collected for the analysis of hematology parameters including leukocytes and platelets.

Time frame:
At Baseline (Day 1), Week 4, Week 8, Week 12, Week 16, Week 20, Week 24 and Week 32 of study
Reported as:
Mean · Giga cells per Liter
Absolute Values of the Hematology Parameters: Leukocytes and Platelets
Giga cells per LiterDTG/ABC/3TC - Mother
Leukocytes, Baseline (Day 1), n=46.48 ± 1.415
Leukocytes, Week 4, n=47.88 ± 2.095
Leukocytes, Week 8, n=48.43 ± 1.959
Leukocytes, Week 12, n=49.15 ± 2.053
Leukocytes, Week 16, n=49.23 ± 1.821
Leukocytes, Week 20, n=410.03 ± 2.848
Leukocytes, Week 24, n=112.60 ± NA
Leukocytes, Week 32, n=25.85 ± 0.636
Platelets, Baseline (Day 1), n=4204.8 ± 37.03
Platelets, Week 4, n=4200.5 ± 2.38
Platelets, Week 8, n=4220.8 ± 16.07
Platelets, Week 12, n=4195.5 ± 25.38
Platelets, Week 16, n=4198.0 ± 10.80
Platelets, Week 20, n=4216.5 ± 10.91
Platelets, Week 24, n=1250.0 ± NA
Platelets, Week 32, n=2206.0 ± 24.04
PrimaryChange From Baseline in Hematology Parameters: Leukocytes and Platelets

Blood samples were collected for the analysis of hematology parameters including leukocytes and platelets. Baseline value (Day 1) is the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline is defined as post-dose visit value minus Baseline value.

Time frame:
Baseline and at Week 4, Week 8, Week 12, Week 16, Week 20, Week 24 and Week 32 of study
Reported as:
Mean · Giga cells per Liter
Change From Baseline in Hematology Parameters: Leukocytes and Platelets
Giga cells per LiterDTG/ABC/3TC - Mother
Leukocytes, Week 4, n=41.40 ± 1.817
Leukocytes, Week 8, n=41.95 ± 2.047
Leukocytes, Week 12, n=42.68 ± 1.173
Leukocytes, Week 16, n=42.75 ± 1.654
Leukocytes, Week 20, n=43.55 ± 2.340
Leukocytes, Week 24, n=14.90 ± NA
Leukocytes, Week 32, n=2-0.65 ± 1.061
Platelets, Week 4, n=4-4.3 ± 39.09
Platelets, Week 8, n=416.0 ± 33.44
Platelets, Week 12, n=4-9.3 ± 39.08
Platelets, Week 16, n=4-6.8 ± 47.16
Platelets, Week 20, n=411.8 ± 45.49
Platelets, Week 24, n=110.0 ± NA
Platelets, Week 32, n=2-4.0 ± 50.91
PrimaryNumber of Participants (Pregnant Women) Who Discontinued the Treatment Due to Adverse Events (AE)

An AE is any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a study treatment. Number of participants (pregnant women) who discontinued the treatment due to adverse events have been presented.

Time frame:
Up to Week 292
Reported as:
Count of participants · Participants
Number of Participants (Pregnant Women) Who Discontinued the Treatment Due to Adverse Events (AE)
ParticipantsDTG/ABC/3TC - Mother
Number of Participants (Pregnant Women) Who Discontinued the Treatment Due to Adverse Events (AE)0
PrimaryNumber of Participants (Pregnant Women) Demonstrated Congenital Malformations

Data for participants (pregnant women) demonstrated congenital malformations was reported.

Time frame:
At delivery (up to Week 40 of pregnancy)
Reported as:
Count of participants · Participants
Number of Participants (Pregnant Women) Demonstrated Congenital Malformations
ParticipantsDTG/ABC/3TC - Mother
Number of Participants (Pregnant Women) Demonstrated Congenital Malformations0
SecondaryTime to Cmax (Tmax) for Dolutegravir

Blood samples were collected at indicated timepoints for PK analysis of dolutegravir at Trimester 2 (Weeks 18-26 of pregnancy), Trimester 3 (Weeks 30-36 of pregnancy) and at 8-12 Weeks postpartum.

Time frame:
Pre-dose and at 1, 2, 3, 4, 6, 8, 12, 24 hours post-dose at Trimester 2 (Weeks 18-26 of pregnancy), Trimester 3 (Weeks 30-36 of pregnancy) and at 8-12 Weeks postpartum
Reported as:
Mean · Hours
Time to Cmax (Tmax) for Dolutegravir
HoursDTG/ABC/3TC - Mother
Trimester 2 (Weeks 18-26 of pregnancy)3.508 ± 1.7082
Trimester 3 (Weeks 30-36 of pregnancy)2.729 ± 0.4877
8-12 Weeks Postpartum4.242 ± 2.0522
SecondaryPre-dose Plasma Concentration (C0) for Dolutegravir

Blood samples were collected at indicated timepoints for PK analysis of dolutegravir at Trimester 2 (Weeks 18-26 of pregnancy), Trimester 3 (Weeks 30-36 of pregnancy) and at 8-12 Weeks postpartum.

Time frame:
Pre-dose at Trimester 2 (Weeks 18-26 of pregnancy), Trimester 3 (Weeks 30-36 of pregnancy) and at 8-12 Weeks postpartum
Reported as:
Geometric mean · Nanograms per milliliter
Pre-dose Plasma Concentration (C0) for Dolutegravir
Nanograms per milliliterDTG/ABC/3TC - Mother
Trimester 2 (Weeks 18-26 of pregnancy)666.9 (149.5 to 2974.6)
Trimester 3 (Weeks 30-36 of pregnancy)1084.6 (676.7 to 1738.3)
8-12 Weeks Postpartum1225.0 (522.8 to 2870.1)
SecondaryUnbound DTG Concentrations in Plasma at 3 and 24 Hours Post Dose of Dolutegravir

Blood samples were collected at indicated timepoints for PK analysis of dolutegravir at Trimester 2 (Weeks 18-26 of pregnancy), Trimester 3 (Weeks 30-36 of pregnancy) and at 8-12 Weeks postpartum.

Time frame:
At 3 hours and 24 hours post dose in Trimester 2 (Weeks 18-26 of pregnancy), Trimester 3 (Weeks 30-36 of pregnancy) and at 8-12 Weeks postpartum
Reported as:
Geometric mean · Micrograms per milliliter
Unbound DTG Concentrations in Plasma at 3 and 24 Hours Post Dose of Dolutegravir
Micrograms per milliliterDTG/ABC/3TC - Mother
At 3 hours post dose in Trimester 27.856 (4.370 to 14.122)
At 3 hours post dose in Trimester 37.371 (4.594 to 11.827)
At 3 hours post dose 8-12 Weeks postpartum6.898 (4.360 to 10.914)
At 24 hours post dose in Trimester 21.798 (0.887 to 3.644)
At 24 hours post dose in Trimester 32.065 (1.229 to 3.471)
At 24 hours post dose 8-12 Weeks postpartum2.881 (1.503 to 5.520)
SecondaryTotal DTG Concentrations in Plasma From Cord Blood and Maternal Blood at the Time of Delivery

Blood samples were collected at the time of delivery for PK analysis of dolutegravir.

Time frame:
At delivery (up to Week 40 of pregnancy)
Reported as:
Mean · Nanograms per milliliter
Total DTG Concentrations in Plasma From Cord Blood and Maternal Blood at the Time of Delivery
Nanograms per milliliterDTG/ABC/3TC - Mother
Cord plasma concentration1436.0 ± 1287.43
Maternal plasma concentration1806.3 ± 1125.04
SecondaryNumber of Participants (Pregnant Women) With Treatment-emergent Genotypic and/or Phenotypic Resistance Who Met Confirmed Virologic Withdrawal Criteria

Number of participants (pregnant women) with treatment-emergent genotypic and/or phenotypic resistance who met confirmed virologic withdrawal criteria are presented. Genotypic and phenotypic analyses were carried out by Monogram Biosciences using, but not limited to, their Standard Phenosense and GenoSure testing methods for protease (PRO) and reverse transcriptase (RT), or with their GeneSeq Integrase and PhenoSense Integrase assays.

Time frame:
Up to Week 32 of study
Reported as:
Count of participants · Participants
Number of Participants (Pregnant Women) With Treatment-emergent Genotypic and/or Phenotypic Resistance Who Met Confirmed Virologic Withdrawal Criteria
ParticipantsDTG/ABC/3TC - Mother
Participants with genotypic resistance0
Participants with phenotypic resistance0
SecondaryNumber of Participants (Pregnant Women) With Live Birth Outcome Categories

Participants (pregnant women) with following live birth outcome categories are reported- Vaginal Birth, Planned Caesarean Section, Unscheduled Caesarean Section and Preterm Delivery.

Time frame:
At delivery (up to Week 40 of pregnancy)
Reported as:
Count of participants · Participants
Number of Participants (Pregnant Women) With Live Birth Outcome Categories
ParticipantsDTG/ABC/3TC - Mother
Vaginal Birth1
Planned Caesarean Section2
Unscheduled Caesarean Section1
Preterm Delivery1
SecondaryGestational Age of Infants

Gestational age is defined as the number of weeks between the first day of the mother's last normal menstrual period and the day of birth. Data for gestational age of infants has been presented.

Time frame:
At birth
Reported as:
Mean · Weeks
Gestational Age of Infants
WeeksDTG/ABC/3TC - Infant
Gestational Age of Infants38.3 ± 1.71
SecondaryNeonatal Length and Head Circumference at Birth

Data for neonatal length and head circumference at birth are reported.

Time frame:
At birth
Reported as:
Mean · Centimeter
Neonatal Length and Head Circumference at Birth
CentimeterDTG/ABC/3TC - Infant
Neonatal Length51.5 ± 3.11
Neonatal Head Circumference34.9 ± 1.65
SecondaryNeonatal Weight at Birth

Data for neonatal weight at birth has been reported.

Time frame:
At birth
Reported as:
Mean · Grams
Neonatal Weight at Birth
GramsDTG/ABC/3TC - Infant
Neonatal Weight at Birth3262.5 ± 731.36
SecondaryNumber of Infants by Their Weight Categories at Birth

Weight of infants at birth were categorized as: Small for Gestational Age (SGA) defined neonates under the 10th percentile in weight, Appropriate for Gestational Age (AGA) characterized neonates between the 10th and 90th percentiles in weight and Large for Gestational Age (LGA) referred to neonates over the 90th percentile in weight.

Time frame:
At birth
Reported as:
Count of participants · Participants
Number of Infants by Their Weight Categories at Birth
ParticipantsDTG/ABC/3TC - Infant
LGA0
AGA4
SGA0
SecondaryNumber of Infants by Appearance, Pulse, Grimace, Activity, and Respiration (APGAR) Score at 1 and 5 Minutes After Birth

APGAR is a quick test to assess the health of new born. The test is performed at 1 and 5 minutes after birth. APGAR scale is determined by evaluating the new born on five categories (appearance, pulse, grimace, activity and respiration) on a scale from zero to two with 2 being the best score, then summing up the values obtained from all five categories. APGAR score ranges from 0 to 10 (Higher score indicates better health) where a score of 7 and above is normal. Number of infants by APGAR score at 1 and 5 minutes after birth are presented.

Time frame:
1 and 5 minutes after birth
Reported as:
Count of participants · Participants
Number of Infants by Appearance, Pulse, Grimace, Activity, and Respiration (APGAR) Score at 1 and 5 Minutes After Birth
ParticipantsDTG/ABC/3TC - Infant
1 Minute, Score 0 to 60
1 Minute, Score 7 to 104
5 Minute, Score 0 to 60
5 Minute, Score 7 to 104
SecondaryPercentage of Participants (Pregnant Women) With Plasma Human Immunodeficiency Virus Type 1 (HIV-1) Ribonucleic Acid (RNA) <50 Copies/Milliliter (c/mL) by Visit

Percentage of participants (pregnant women) with plasma HIV-1 RNA \<50 c/mL are presented. Plasma samples were collected for quantitative analysis of HIV-1 RNA.

Time frame:
At Week 4, Week 8, Week 12, Week 16, Week 20, Week 24, Week 28 and Week 32 of study
Reported as:
Number · Percentage of participants
Percentage of Participants (Pregnant Women) With Plasma Human Immunodeficiency Virus Type 1 (HIV-1) Ribonucleic Acid (RNA) <50 Copies/Milliliter (c/mL) by Visit
Percentage of participantsDTG/ABC/3TC - Mother
Week 4, n=4100
Week 8, n=4100
Week 12, n=4100
Week 16, n=4100
Week 20, n=4100
Week 24, n=2100
Week 28, n=1100
Week 32, n=2100
SecondaryPercentage of Participants (Pregnant Women) With Plasma HIV-1 RNA <400 c/mL by Visit

Percentage of participants (pregnant women) with plasma HIV-1 RNA \<400 c/mL are presented. Plasma samples were collected for quantitative analysis of HIV-1 RNA.

Time frame:
At Week 4, Week 8, Week 12, Week 16, Week 20, Week 24, Week 28 and Week 32 of study
Reported as:
Number · Percentage of participants
Percentage of Participants (Pregnant Women) With Plasma HIV-1 RNA <400 c/mL by Visit
Percentage of participantsDTG/ABC/3TC - Mother
Week 4, n=4100
Week 8, n=4100
Week 12, n=4100
Week 16, n=4100
Week 20, n=4100
Week 24, n=2100
Week 28, n=1100
Week 32, n=2100
SecondaryAbsolute Values of Cluster of Differentiation 4 (CD4+) T Cell Counts by Visit

Blood samples were collected for the analysis of CD4+ T cell counts using cytometry.

Time frame:
At Baseline (Day 1), Week 4, Week 8, Week 12, Week 16, Week 20, Week 24, Week 28 and Week 32 of study
Reported as:
Mean · Cells per cubic millimeter
Absolute Values of Cluster of Differentiation 4 (CD4+) T Cell Counts by Visit
Cells per cubic millimeterDTG/ABC/3TC - Mother
Baseline (Day 1), n=4476.3 ± 123.31
Week 4, n=4569.5 ± 238.51
Week 8, n=4569.8 ± 296.43
Week 12, n=4575.0 ± 331.22
Week 16, n=4626.8 ± 270.63
Week 20, n=4791.5 ± 524.96
Week 24, n=2874.5 ± 516.90
Week 28, n=1488.0 ± NA
Week 32, n=2677.5 ± 40.31
SecondaryChange From Baseline in CD4+ T Cell Counts by Visit

Blood samples were collected for the analysis of CD4+ T cell counts using cytometry. Baseline value (Day 1) is the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline is defined as post-dose visit value minus Baseline value.

Time frame:
Baseline and at Week 4, Week 8, Week 12, Week 16, Week 20, Week 24, Week 28 and Week 32 of study
Reported as:
Mean · Cells per cubic millimeter
Change From Baseline in CD4+ T Cell Counts by Visit
Cells per cubic millimeterDTG/ABC/3TC - Mother
Week 4, n=493.3 ± 124.64
Week 8, n=493.5 ± 174.54
Week 12, n=498.8 ± 208.50
Week 16, n=4150.5 ± 148.73
Week 20, n=4315.3 ± 402.00
Week 24, n=2353.0 ± 332.34
Week 28, n=198.0 ± NA
Week 32, n=2246.0 ± 97.58
SecondaryNumber of Participants (Pregnant Women) With Disease Progression

Disease progression included HIV-associated conditions, acquired immunodeficiency syndrome (AIDS) and death. Number of participants (pregnant women) with disease progression to Centers for Disease Control and Prevention (CDC) class C or death have been presented.

Time frame:
Up to Week 32 of study
Reported as:
Count of participants · Participants
Number of Participants (Pregnant Women) With Disease Progression
ParticipantsDTG/ABC/3TC - Mother
Number of Participants (Pregnant Women) With Disease Progression0
PrimaryNumber of Participants (Pregnant Women) With Adverse Events (AE) as Per Severity Grades

Number of participants (pregnant women) with adverse events (AE) as per severity grades were presented. Grade 1 is mild, grade 2 is moderate, grade 3 is severe or medically significant but not immediately life-threatening and grade 4 is life-threatening consequences; urgent intervention required.

Time frame:
Up to 292 Weeks
Reported as:
Count of participants · Participants
Number of Participants (Pregnant Women) With Adverse Events (AE) as Per Severity Grades
ParticipantsDTG/ABC/3TC - Mother
Grade 12
Grade 22
Grade 30
Grade 40

Adverse events

Collected over All-cause mortality, serious adverse events (SAEs) and non-serious adverse events (non-SAEs) were collected up to Week 328. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
DTG/ABC/3TC - Mother0/4 (0%)1/4 (25%)4/4 (100%)
DTG/ABC/3TC - Infant———
Most frequent serious events
Most frequent serious events
EventDTG/ABC/3TC - MotherDTG/ABC/3TC - Infant
Premature babyPregnancy, puerperium and perinatal conditions1/4—
Most frequent other events
Showing 10 of 15
Most frequent other events
EventDTG/ABC/3TC - MotherDTG/ABC/3TC - Infant
Respiratory tract infectionInfections and infestations2/4—
AstheniaGeneral disorders2/4—
HeadacheNervous system disorders2/4—
NephropathyRenal and urinary disorders2/4—
CystitisInfections and infestations1/4—
GastroenteritisInfections and infestations1/4—
Oral herpesInfections and infestations1/4—
Respiratory tract infection viralInfections and infestations1/4—
Vaginal infectionInfections and infestations1/4—
MigraineNervous system disorders1/4—

Baseline characteristics

Baseline Characteristics data was collected only in pregnant women (enrolled population/study participants) and not in infants, as infants were not considered as enrolled per study design.

Age, Continuous
Age, Continuous(Years)DTG/ABC/3TC - Mother
Mean29.3 ± 5.56
Sex: Female, Male
Sex: Female, Male(Participants)DTG/ABC/3TC - Mother
Female4
Male0
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)DTG/ABC/3TC - Mother
White/Caucasian/European heritage4
09

Study locations

3 sites
  • GSK Investigational Site
    Orel, 302040, Russian Federation
  • GSK Investigational Site
    St. Petersburg, 196645, Russian Federation
  • GSK Investigational Site
    Madrid, 28046, Spain
10

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

11

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2014 to primary completion in Oct 2018, 46 months.

Results were first posted in Feb 2022, 3 years 3 months after primary completion. A results delay was requested in Aug 2020.

Of 57 industry-sponsored phase 3 interventional studies under HIV Infections, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 30. This study's 46 months is above that.

Counting every sponsor, half of 101 studies reached it within 27 months; a quarter within 20 and three quarters within 46.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 27, 2014
First posted
Mar 3, 2014
StartActual
Dec 17, 2014
Primary completionActual
Oct 22, 2018
CompletionActual
Sep 15, 2021
Results delay requested
Aug 5, 2020
Results first posted
Feb 18, 2022
Last update
Oct 6, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 6, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT02075593
Lead sponsor
ViiV Healthcare
Collaborators
GlaxoSmithKline
Responsible party
Sponsor
First posted
Mar 3, 2014
Start date
Dec 17, 2014
Primary completion
Oct 22, 2018
Completion
Sep 15, 2021
Results posted
Feb 18, 2022
Last update
Oct 6, 2022

Study contacts

GSK Clinical Trials
study director · ViiV Healthcare

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dolutegravir

Start the discussion